N-(4-methyl-thiazol-2-yl)-benzene-1,4-diamine | 1745-19-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-methyl-thiazol-2-yl)-benzene-1,4-diamine
• 英文别名: 1-N-(4-methyl-1,3-thiazol-2-yl)benzene-1,4-diamine；4-N-(4-methyl-1,3-thiazol-2-yl)benzene-1,4-diamine
• CAS: 1745-19-3
• 化学式: C₁₀H₁₁N₃S
• mdl: MFCD09941772
• 分子量: 205.283
• InChiKey: QQTIBNSKYMVQSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  79.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF
  申请人：Duke University

  公开号：EP2637658A1

  公开（公告）日：2013-09-18
• [EN] COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF<br/>[FR] COMPOSITIONS ET PROCÉDÉS ASSOCIÉS À DES COMPOSÉS ACTIVATEURS DE FACTEUR DE TRANSCRIPTION DE CHOC THERMIQUE ET DES CIBLES DE CEUX-CI
  申请人：UNIV DUKE

  公开号：WO2012064715A1

  公开（公告）日：2012-05-18

  The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.